Potential for Core Fucose-Targeted Therapy Against HBV Infection of Human Normal Hepatocytes.

Shinji Takamatsu, Chiharu Morita, Daisuke Sakon, Kotaro Nakamura, Honoka Hishii, Jumpei Kondo, Keiji Ueda, Eiji Miyoshi

Abstract read

In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shinji TakamatsuDepartment of Molecular Biochemistry and Clinical Investigation, Graduate School of Medicine, The University of Osaka, 1-7 Yamada-oka, Suita 565-0871, Osaka, Japan.ORCID 0000-0003-1996-7740

Chiharu MoritaDepartment of Virology, Graduate School of Medicine, The University of Osaka, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.

Daisuke SakonDepartment of Molecular Biochemistry and Clinical Investigation, Graduate School of Medicine, The University of Osaka, 1-7 Yamada-oka, Suita 565-0871, Osaka, Japan.

Kotaro NakamuraDepartment of Molecular Biochemistry and Clinical Investigation, Graduate School of Medicine, The University of Osaka, 1-7 Yamada-oka, Suita 565-0871, Osaka, Japan.

Honoka HishiiDepartment of Molecular Biochemistry and Clinical Investigation, Graduate School of Medicine, The University of Osaka, 1-7 Yamada-oka, Suita 565-0871, Osaka, Japan.

Jumpei KondoDepartment of Molecular Biochemistry and Clinical Investigation, Graduate School of Medicine, The University of Osaka, 1-7 Yamada-oka, Suita 565-0871, Osaka, Japan.ORCID 0000-0002-1350-0480

Keiji UedaDepartment of Virology, Graduate School of Medicine, The University of Osaka, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan.ORCID 0000-0001-5641-8105

Eiji MiyoshiDepartment of Molecular Biochemistry and Clinical Investigation, Graduate School of Medicine, The University of Osaka, 1-7 Yamada-oka, Suita 565-0871, Osaka, Japan.ORCID 0000-0002-9430-2362

Funding

Japan Agency for Medical Research and Development 23fk0310505h0002

6 · The paper itself

Abstract

Core fucose is one of the most important glycans in HBV infection. In this study, we investigated whether

Indexed as

Antiviral AgentsFucoseHepatitis BHepatitis B virusHepatocytesLectinsHepatitis B e AntigensHep G2 CellsHumansVirus InternalizationVirus ReplicationAntiviral AgentsFucoseHepatitis B e AntigensLectinsFut8glycotherapyHBVPhoSLPXB cells

Identifiers

PMID41012670

DOI10.3390/v17091242

PMCPMC12474135

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.